PREVALENCE OF VIM- AND GIM-PRODUCING ACINETOBACTER BAUMANNII FROM PATIENTS WITH SEVERE URINARY TRACT INFECTION

SMILINE AS GIRIJA1*, VIJAYASHREE PRIYADHARSINI JAYASEELAN2 and PARAMASIVAM ARUMUGAM3

1Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India
2BRULAC-DRC, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India
3Department of Human Genetics, Centre for Cellular and Molecular Biology, Hyderabad, India

(Received: 21 May 2018; accepted: 12 June 2018)

Carbapenems are administered as the final drug of choice for treating complicated nosocomial infections caused by multidrug-resistant Acinetobacter baumannii strains. It is currently a worldwide issue that metallo-β-lactamases (MBLs) as carbapenem-hydrolyzing enzymes are one of the major drug resistance mechanisms. This investigation is thus aimed to assess the prevalence and characterize the MBL-producing strains of A. baumannii both by phenotypic assays and by genotypic characterization. A total of 73 isolates of A. baumannii were phenotypically and genotypically characterized from patients (N = 1,000) with severe urinary tract infection. Tested strains were subjected to double disc synergy testing (DDST) by Kirby–Bauer disc diffusion method with imipenem (IMP) and IMP/EDTA combination discs. Plasmid DNA was molecularly screened for MBL-encoding blaIMP, blaVIM, blaGIM, and blaNDM genes by PCR for the genetic relatedness of the MBL genes with carbapenem resistance. Carbapenem resistance profile showed 100%, 45%, and 49% non-susceptibility against imipenem, doripenem, and meropenem, respectively. Altogether 42.46% (n = 31) of the isolates showed MBL production upon double disc phenotypic test with IMP and IMP/EDTA discs. The blaVIM and blaGIM were detected in 34.24% (n = 25) and 16.43% (n = 12) of the isolates, respectively, while the co-occurrence of blaVIM and blaGIM was 2.73% among the isolates. DDST-positive isolates showed 21.19% and 9.58% strains positive for blaVIM and blaGIM, respectively, whereas 1.36% of the strains for both genes. None of the strains yielded blaIMP and blaNDM genes. The findings of this study showed prevalence of carbapenem resistance among A. baumannii from urine samples and the frequency of blaVIM and blaGIM.

Keywords: A. baumannii, carbapenems, blaIMP, blaVIM, blaGIM, blaNDM

*Corresponding author; E-mail: smilinejames25@gmail.com
Introduction

*Acinetobacter baumannii*, a pleomorphic, aerobic Gram-negative bacterium, has emerged as one of the critical multidrug-resistant nosocomial pathogens worldwide [1]. *A. baumannii* is considered as one among the top seven pathogens threatening the patient’s healthcare and as an unmet medical need [2]. *A. baumannii* infections are considered with great concern due to their resistance pattern exhibited to several classes of antibiotics, especially carbapenems [3] and are considered as sentinels of drug resistance with the designation as carbapenem-resistant *A. baumannii* [4]. Among several mechanisms related to carbapenem resistance, the resistance exhibited due to carbapenem-hydrolyzing enzymes is frequently considered worldwide [5]. Based on the Ambler classification, these enzymes belong to class B metallo-β-lactamase (MBL) and class D OXA-type carbapenemases and most of them are mediated by plasmids [6].

MBLs are further classified into several families with *bla*<sub>VIM</sub>, *bla*<sub>IMP</sub>, *bla*<sub>GIM</sub>, and more recently *bla*<sub>NDM</sub> and are located in the gene cassettes of class 1 integrons with *bla*<sub>IMP</sub> in class 3 integrons [7, 8]. For the optimal MBL activity, divalent cations are required as cofactors with further action of one or two zinc ions for their catalytic activity with chelators as inhibitory agents [9]. These MBLs are highly potent in hydrolyzing all the β-lactam antibiotics except the monobactams such as aztreonam [10] and there are no known MBL inhibitors [11]. Dissemination of MBL-encoding genes is highly popular among the plasmids or by integron-borne mobile gene cassettes through horizontal gene transfer mechanisms [12]. As a dominant MBL variant, *bla*<sub>NDM</sub> [13] and *bla*<sub>VIM</sub>-2 [14] have recently emerged with worldwide reports.

Earlier studies have reported the emergence of *bla*<sub>VIM</sub>-, *bla*<sub>IMP</sub>-, and *bla*<sub>GIM</sub>-based carbapenem resistance among *A. baumannii* [15, 16] along with the increased incidences of *bla*<sub>NDM</sub>-based resistance [17, 18]. Detection of these MBLs is often based on the inhibitor-based test using metal ion chelators, such as ethylene diamine tetra acetic acid (EDTA) or thio-based compounds [19]. Among several phenotypic detections, Clinical Laboratory Standards Institute (CLSI) [21] advocates the application of modified Hodge’s test, CarbaNP test, and/or a molecular-based assay for the confirmation of the MBL producers among *Enterobacteriaceae* and *A. baumannii* strains. Genotypic characterization of the MBL-based genetic determinants *bla*<sub>VIM</sub>, *bla*<sub>IMP</sub>, *bla*<sub>GIM</sub>, and *bla*<sub>NDM</sub> is detected by polymerase chain reactions (PCRs) and clonal relatedness is analyzed by various molecular methods [20].

With this background, the present investigation aimed to phenotypically and genotypically characterize the MBL producers among *A. baumannii* strains with the phylogenetic assessment of the MBL-based genetic determinants such as...
bla\textsubscript{VIM}, bla\textsubscript{IMP}, bla\textsubscript{GIM}, and bla\textsubscript{NDM} screened from the patients with severe urinary tract infections from South India.

**Materials and Methods**

**Study design**

A total of 73 consecutive and non-repetitive *A. baumannii* isolates, which were isolated and identified for a period of 12 months (2014–2015) from urine samples of patients with severe urinary tract infections (*N* = 1,000), were phenotypically and genotypically confirmed by conventional microbiological analytical tests and PCR, respectively, at the Department of Microbiology. These characterized strains were subjected to antibiotic susceptibility test by standard Kirby–Bauer disc diffusion method using imipenem (IMP; 10 μg), doripenem (10 μg), and meropenem (10 μg) for the carbapenem resistance profile of the selected strains under study.

**Phenotypic confirmatory test**

With the observation and record of the carbapenem resistance, all the strains were further subjected for phenotypic double disc synergy testing (DDST) as per the CLSI (2012) [21]. All the test strains were prepared as fresh broth cultures and lawn was made onto sterile Mueller–Hinton agar (MHA; Hi-Media, Mumbai). For the MBL detection, two discs were used for the profile such as IMP (10 μg) (Hi-Media) and IMP/EDTA. An amount of 0.5 M EDTA was prepared by dissolving 186.1 g of disodium EDTA-2H\textsubscript{2}O in 1,000 ml of distilled water (pH 8.0) and was sterilized by autoclaving. An amount of 10 μl was added onto one of the IMP discs to obtain the desired concentration of IMP/EDTA (10/750 μg). The discs were placed onto the surface of the MHA at a distance of 20 mm from each. The plates were then incubated for a period of 24 h at 37 °C. The increase in zone size of ≥7 mm around the IMP/EDTA disc than IMP was interpreted as MBL producers.

**Molecular detection of bla\textsubscript{VIM}, bla\textsubscript{IMP}, bla\textsubscript{GIM}, and bla\textsubscript{NDM} genetic determinants in MBL producers**

**Extraction of plasmid DNA and PCR amplification.** All the strains were stored at –80 °C in 80%/20% (v/v) glycerol in Luria–Bertani media for genetic stability of
Plasmid DNA was extracted from fresh cultures of *A. baumannii* using Qiagen extraction kit in accordance with the manufacturer’s instructions and was stored in −20 °C until further use. An amount of 15 μl of amplification reaction mixtures was prepared by mixing 7.8 μl of 2× Master Mix (Takara, Japan) in 5.6 μl of double distilled water. Specific forward primer and reverse primer (Eurofins Genomic India Pvt Ltd., Bangalore, India) of *bla*VIM, *bla*IMP, *bla*GIM, and *bla*NDM were added using the standard PCR conditions (Table I). PCR amplification was carried out and the resulting PCR amplicons were examined in 1% agarose gel electrophoresis containing ethidium bromide, which was visualized in a gel documentation system. The 100 bp DNA ladder was used to confirm the amplicon size.

**Results**

Preliminary screening for the carbapenem resistance tests showed 100%, 45%, and 49% non-susceptibility against imipenem, doripenem, and meropenem, respectively, as per CLSI zone interpretative criteria (Figure 1). DDST with IMP and IMP/EDTA discs yielded 42.46% (*n* = 31) of the isolates as MBL producers (Table II). A total of 37 isolates (50.68%) showed resistance to all the carbapenems tested with 31.50% (*n* = 23) DDST-positive (Figure 2).

Genotypic characterization of the MBL genetic determinants showed the presence of *bla*VIM and *bla*GIM in 34.24% (*n* = 25) and 16.43% (*n* = 12) of the isolates. Co-occurrence of *bla*VIM and *bla*GIM was observed in 2.73% (*n* = 2) of the isolates. DDST-positive isolates showed 21.19% (*n* = 16) positive for *bla*VIM and 9.58% (*n* = 7) positive for *bla*GIM determinants (Table III and Figure 3). Among the two isolates with both *bla*VIM and *bla*GIM genes, only one strain was DDST-positive. However, none of the strains yielded *bla*IMP and *bla*NDM genes.

**Discussion**

A wide range of nosocomial infections encompassing meningitis, septicemia, pneumonia, and skin and wound infections are caused by *A. baumannii* and are considered as a major challenge in the patient healthcare [23]. Carbapenems such as imipenem, doripenem, meropenem, and ertapenem are considered as the last resort antibiotics in the treatment of severe and complicated infections established by multidrug-resistant *A. baumannii* [24]. In recent decades, resistance to carbapenems is highly reported [25]. The present investigation has also recorded a total of 37 isolates (*N* = 73) as carbapenem-resistant strains. All the strains fall under the
<table>
<thead>
<tr>
<th>Target gene</th>
<th>Primers</th>
<th>Sequence (5′–3′)</th>
<th>Annealing temperature (°C)</th>
<th>Amplicon size (bp)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>bla&lt;sub&gt;IMP&lt;/sub&gt;</td>
<td>IMP – F’</td>
<td>GAATAGAATGGTTAACTCTC</td>
<td>53</td>
<td>188</td>
<td>[26]</td>
</tr>
<tr>
<td></td>
<td>IMP – R’</td>
<td>CCAAACCCTAGTTATC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bla&lt;sub&gt;VIM&lt;/sub&gt;</td>
<td>VIM – F’</td>
<td>GTTTGGTCGCATATCGCAAC</td>
<td>53</td>
<td>382</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VIM – R’</td>
<td>AATGCAGCAGAACAGGATAG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bla&lt;sub&gt;GIM&lt;/sub&gt;</td>
<td>GIM – F’</td>
<td>TCAATTAGCTCTGGGCTGAC</td>
<td>53</td>
<td>726</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GIM – R’</td>
<td>CGGAACGACCATTGGAATGG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bla&lt;sub&gt;NDM-1&lt;/sub&gt;</td>
<td>NDM – F’</td>
<td>GTTTTGCGATCTGGTTTC</td>
<td>52</td>
<td>621</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NDM – R’</td>
<td>CGGAATGGCTCATCACGATC</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: ESBL: extended-spectrum β-lactamase; IMP: imipenem.
Figure 1. Frequency of resistance exhibited by A. baumannii toward the antibiotics tested

Table II. Preliminary screening and phenotypic confirmation of ESBL producers among the A. baumannii isolates as per CLSI (2012) [21]

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Preliminary screening</th>
<th>DDST</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. baumannii</td>
<td>100%</td>
<td>Antibiotics</td>
</tr>
<tr>
<td>(N = 73)</td>
<td>(n = 73)</td>
<td>Positive (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Imipenem and imipenem + EDTA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.46 (n = 31)</td>
</tr>
</tbody>
</table>

Note: ESBL: extended-spectrum β-lactamase; DDST: double disc synergy test; EDTA: ethylene diamine tetra acetic acid; CLSI: Clinical Laboratory Standards Institute.

Figure 2. The specificity of detection methods employed for identifying drug-resistant strains
imipenem-resistant strains of A. baumannii. One hundred percent of the strains showing imipenem resistance are also reported in an earlier study from South India [27]. Imipenem showing intrinsic resistance in A. baumannii is reported [28] and in many earlier studies the isolates of A. baumannii for carbapenemase and MBL production were categorized based on imipenem susceptibility and resistance patterns [29]. Several studies have recorded the higher incidences of imipenem non-susceptibility/resistance [30, 31]. This study has recorded nearly 60%–65% of non-susceptibility against doripenem and meropenem with only 15.06% and 13.69% susceptibility against the same, respectively. Similar observations were recorded from Turkey with 66.6% resistance against meropenem and 49.9% against doripenem [32]. Another study from USA showed 68% and 80% non-susceptibility to meropenem and doripenem, respectively [33]. On the contrary, an earlier study from Punjab recorded only 6% of the isolates to exhibit non-susceptibility against doripenem and meropenem [34]. Along with these routinely administered carbapenems, administration of ertapenem induced no impact on the susceptibility pattern of imipenem and was directly associated with the reduced use of imipenem and ciprofloxacin among A. baumannii [35].

### Table III.

Distribution of \( \text{bla}_{\text{IMP}}, \text{bla}_{\text{NDM}}, \text{bla}_{\text{VIM}}, \) and \( \text{bla}_{\text{GIM}} \) genes among the MBL producers of A. baumannii

<table>
<thead>
<tr>
<th>MBL-positive isolates</th>
<th>Target genes studied (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. baumannii (( N = 73 ))</td>
<td>( \text{bla}_{\text{IMP}} )</td>
</tr>
<tr>
<td>( (n = 25) )</td>
<td>0</td>
</tr>
<tr>
<td>( (n = 12) )</td>
<td>( (n = 2) )</td>
</tr>
</tbody>
</table>

**Note:** MBL: metallo-\( \beta \)-lactamase.

![Figure 3. Electrophoretogram of (a) \( \text{bla}_{\text{VIM}} \) gene and (b) \( \text{bla}_{\text{GIM}} \) amplicons run along with 100 bp DNA ladder (Lane 1).](image)
limits *per se* the omission of ertapenem under carbapenem-resistant profile for the test organisms under the study.

Phenotypic detection of MBL production was observed using IMP and IMP/EDTA potentiation disc test. Among the tested isolates, with 100% resistance against imipenem and nearly 63% resistance against doripenem and meropenem, phenotypic confirmation was achieved only in 42.46% of the isolates. In addition, DDST positivity co-related only with 31.50% \( (n = 23) \) of the isolates confirmed by Kirby–Bauer diffusion assay. Among the 73 imipenem-resistant isolates, only 31 were DDST-positive, which might be due to the \( \text{bla}_{\text{IMP}} \) gene cassettes associated with integrons that do not phenotypically express the \( \text{bla}_{\text{IMP}} \) type of genetic determinants [36]. About 21.91% and 9.58% of the isolates among 31 DDST-positive *A. baumannii*, expressing \( \text{bla}_{\text{VIM}} \) and \( \text{bla}_{\text{GIM}} \), suggest the role of VIM- and GIM-type \( \beta \)-lactamases in inducing carbapenem resistance. Although variants of IMP and VIM are frequently reported, MBL genetic determinants can be restricted to certain geographical regions with members of SPM, GIM, and SIM variants [37]. Genotypic characterization of MBL determinants with phenotypic-positive DDST showing 6 and 19 negative isolates may be again related to the variants exhibited among class I integron structures, which are frequently detected among *A. baumannii* [38, 39]. Comparative analysis between phenotypic and genotypic data observed in the present investigation suggests DDST to be highly reliable and easy to perform for the preliminary screening of MBL production with the reports varying from 7.5% [40] to 70.9% [27].

Molecular detection of the genetic determinants of MBL production such as \( \text{bla}_{\text{VIM}} \), \( \text{bla}_{\text{IMP}} \), \( \text{bla}_{\text{GIM}} \), and \( \text{bla}_{\text{NDM}} \) was observed using PCR. All the imipenem-resistant isolates \( (n = 73) \) of *A. baumannii* showed \( \text{bla}_{\text{IMP}} \) and \( \text{bla}_{\text{NDM}} \) negative. In comparison with the carbapenem-resistant profile (imipenem − 100%, doripenem − 61.64%, and meropenem − 67.12%) and DDST-positive isolates \( (n = 31) \), only 25 (34.24%) and 12 (16.43%) showed the presence of \( \text{bla}_{\text{VIM}} \) and \( \text{bla}_{\text{GIM}} \). This variation might be due to the other non-enzymatic mechanisms, such as presence of efflux pumps, role of outer membrane proteins etc., exhibiting the carbapenem resistance property among *A. baumannii* [41]. A widespread distribution of MBL producers among *A. baumannii* is observed worldwide such as 70%–90% in India, 27.1% in Pakistan, and considerable numbers in Europe, Australia, and Africa [42, 43].

Among the MBL genetic determinant, co-occurrences of the genes are also not uncommon. The studies record the different patterns of co-occurring MBL genes from different countries [44]. In view with this, the present study also records the co-occurrence of \( \text{bla}_{\text{VIM}} \) and \( \text{bla}_{\text{GIM}} \) in two isolates (2.73%). Comparative analysis between phenotypic and genotypic detection also shows a significant report. The study records 21.91% \( (n = 16) \) and 9.58% \( (n = 7) \) with DDST + \( \text{bla}_{\text{VIM}} \) and DDST + \( \text{bla}_{\text{GIM}} \) positivity, respectively, with one 1.36% of
the isolate showing DDST + bla\textsubscript{VIM} + bla\textsubscript{GIM} positivity. In an earlier study from Nepal, co-existence of bla\textsubscript{OXA-23} and bla\textsubscript{NDM-1} was detected [45] with the presence of other class B MBLs, such as bla\textsubscript{VIM} and bla\textsubscript{GIM}. One of the recent studies showed the presence of bla\textsubscript{VIM} only in imipenem-resistant genomic species of 13TU – A. baumannii and not in other isolates [46]. These results when compared with the present investigation vividly portray the differences in the phenotypic and genotypic traits against the carbapenems among the A. baumannii species existing in different geographic locale.

A. baumannii traits acquire different kinds of antimicrobial resistance and are emerging as a dreadful nosocomial pathogen leading to complications in the treatment and control. Frequency of MBLs and the distribution of their genetic determinants restrict the administration of carbapenems against A. baumannii. Thus, this study concludes by stating the need for the proper and periodical antimicrobial surveillance programs for using carbapenems against A. baumannii isolates, as there exists a variation in the resistance pattern and the associated genes in inducing the carbapenemase resistance.

Acknowledgements

The authors are grateful to Dr. Senthil Pragash Dandapany (PhD candidate, MAHER), Associate Professor, Department of Microbiology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Tamil Nadu, for rendering the culture strains for the study.

Conflict of Interest

None.

References


20. Srinivasan, V. B., Rajamohan, G., Pancholi, P., Stevenson, K., Tadesse, D., Patchane, P., Marcon, M., Gebreyes, W. A.: Genetic relatedness and molecular characterization of


